On June 1, 2020, Aaron C. Tan et al. published an online review article entitled "Management of glioblastoma: State of the art and future directions" in the journal CA (IF=223). The review included " incidence And mortality ", " histopathology and classification ", " treatment management ", " future direction " and other 4 parts:
glioblastoma is the most common malignant primary brain Tumor. Overall, the prognosis of patients with this disease is poor, with a median survival time of less than 2 years. Males make up the majority, and the incidence increases with age. In the newly diagnosed environment, standard treatments include surgery, followed by radiotherapy plus temozolomide and so on. Tumor therapy with low-intensity communication can also be used simultaneously with adjuvant temozolomide therapy. When relapses, there is no standard care. However, depending on the patient's condition, surgery, radiotherapy and chemotherapy or systemic therapy with bevacizumab and are all potential options. In the multi-modal management method, support and palliative care are still important considerations in the entire disease process.
recently classified glioblastoma based on molecular profiling, especially different citrate dehydrogenase (IDH) mutation status , which is the result of further understanding of the underlying pathogenesis of the disease. Obviously, better treatment options are needed, and great efforts have been made to explore immunotherapy and precision oncology methods. However, compared with other solid tumors, biological factors such as blood-brain barrier, unique tumors and immune microenvironment are facing major challenges in developing new therapies . Innovative clinical trial designs with biomarker enrichment strategies are needed to ultimately improve the prognosis of patients with glioblastoma.
glioblastoma is the most malignant glioma in astrocytic tumors. tumors are located under the cortex, and most of them grow throughout the supratentorial cerebral hemisphere. It is infiltrating growth, often invading several brain lobes, and invading deep structures. It can also spread through the corpus callosum to the opposite cerebral hemisphere. The frontal lobe is most common in .
glioblastoma is the most common malignant primary brain tumor, accounts for about 57% of all gliomas and 48% of all primary malignant central nervous system (CNS) tumors. Although glioblastoma therapy combines the latest advances in surgery, radiation therapy, systemic therapy (chemotherapy), targeted therapy and supportive care, still has a poor overall prognosis and low long-term survival rate.
In addition, the morbidity associated with the gradual decline in nervous system function and quality of life can have devastating effects on patients, caregivers and families. The era of precision oncology and immunotherapy heralds the development of more effective and tolerable therapies to address this aggressive disease.
is a new therapeutic target for glioblastoma (picture from CA)
recently based on molecular profiling analysis, , especially 2z citrate dehydrogenase (IDH) mutation status classifies glioblastoma, this It is the result of a further understanding of the underlying pathogenesis of the disease . Obviously, better treatment options are needed, and great efforts have been made to explore immunotherapy and precision oncology methods.
However, compared with other solid tumors, faces major challenges in the development of new therapies with biological factors such as the blood-brain barrier, unique tumors and immune microenvironment. requires innovative clinical trial design with biomarker enrichment strategies to ultimately improve the prognosis of patients with glioblastoma. This review of covers the latest advances in glioblastoma treatment and the future directions of precision oncology and immunotherapy.
reference message:
https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21613
